Coumarin Resistance

Description

Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement (Yuan et al., 2005). The dose requirement is highly variable, both interindividually and interethnically.Variation in the VKORC1 gene is believed to be the most important individual predictor of warfarin dose, accounting for about 30% of the variance observed in dosing (Ross et al., 2010).

Clinical Features

Phenotypes and symptoms related to Coumarin Resistance

  • Abnormality of metabolism/homeostasis
  • Atrial fibrillation
  • Abnormality of blood and blood-forming tissues
  • Deep venous thrombosis

Incidence and onset information

— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)
No data available about the known clinical features onset.

Alternative names

Coumarin Resistance Is also known as coumarin, poor metabolism of, warfarin resistance.

Researches and researchers

Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.


Mendelian

Accelerate your rare disease diagnosis with us

Learn more

Coumarin Resistance Recommended genes panels

Panel Name, Specifity and genes Tested/covered
VKORC1 Sequencing.

By Cincinnati Children's Hospital Medical Center Laboratory of Genetics and Genomics Cincinnati Children's Hospital Medical Center (United States).

VKORC1
Specificity
100 %
Genes
34 %
Warfarin resistance.

By Sheffield Diagnostic Genetics Service Sheffield Children's NHS Foundation Trust (United Kingdom).

VKORC1
Specificity
100 %
Genes
34 %
Vitamin K-Dependent Clotting Factors, Combined Deficiency of, 2.

By CGC Genetics (Portugal).

VKORC1
Specificity
100 %
Genes
34 %
Susceptibility to warfarin (CYP2C9 and VKORC1 genes).

By CGC Genetics (Portugal).

VKORC1, CYP2C9
Specificity
100 %
Genes
67 %
Pharmacogenetic panel for cardiology.

By CGC Genetics (Portugal).

VKORC1, CYP2C19, CYP2C9, CYP2D6
Specificity
50 %
Genes
67 %
Hereditary combined deficiency of vitamin K-dependent clotting factors, type 2 (sequence analysis of VKORC1 gene).

By CGC Genetics (Portugal).

VKORC1
Specificity
100 %
Genes
34 %
Warfarin resistance (sequence analysis of VKORC1 gene).

By CGC Genetics (Portugal).

VKORC1
Specificity
100 %
Genes
34 %
Warfarin resistance (sequence analysis of VKORC1 gene).

By CGC Genetics (Portugal).

VKORC1
Specificity
100 %
Genes
34 %

We have 106 more panels available in our App

Get the app

Sources and references

You can check the following sources for additional information.

OMIM Rare Disease Search Engine

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like SEPTO-OPTIC DYSPLASIA SPECTRUM FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2 MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6 CRANIOSYNOSTOSIS 5, SUSCEPTIBILITY TO; CRS5 GLYCOGEN STORAGE DISEASE DUE TO MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTAL RETARDATION, AND EAR ANOMALIES SYNDROME; CHIME

Need help with a diagnosis?

Learn more about how to achieve it with Mendelian


Learn more